A systematic review of vinpocetine therapy in acute ischaemic stroke

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objectives: To determine whether vinpocetine decreases short- and long- term case fatality and proportion of dependent survivors if administered within 2 weeks of stroke onset. Methods: All published and unpublished trials were attempted to be identified using the standard search strategy of the Cochrane Collaboration Stroke Review Group, using MEDLINE searches performed with all known manufacturer code names and trade names of vinpocetine and by contacting manufacturers of vinpocetine to give information of all randomised controlled trials on vinpocetine in stroke. Researchers who participated in trials on vinpocetine in Hungary were asked for further information. Only truly randomised, unconfounded clinical trials that compared the effect of vinpocetine to either placebo or another reference treatment for acute stroke where treatment started no later than 14 days after stroke onset were eligible for inclusion. Data synthesis and analysis was performed using the Cochrane Review Manager software (Rev Man version 3.0). Results: Among the identified studies on vinpocetine in stroke, only one fulfilled the selection criteria for inclusion in the review. No death occurred in the study groups and no statistically significant difference was found in dependency between the treatment and the placebo groups. No adverse effects were reported. Conclusions: Based on only one small randomised controlled unconfounded study, presently there is not enough evidence to decide whether the administration of vinpocetine does or does not decrease case fatality and dependency in acute stroke.

Original languageEnglish
Pages (from-to)349-352
Number of pages4
JournalEuropean Journal of Clinical Pharmacology
Volume55
Issue number5
DOIs
Publication statusPublished - 1999

Fingerprint

vinpocetine
Stroke
Therapeutics
Names
Randomized Controlled Trials
Placebos
Hungary
MEDLINE
Patient Selection
Survivors

Keywords

  • Human
  • Ischaemic stroke
  • Vinpocetine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A systematic review of vinpocetine therapy in acute ischaemic stroke. / Bereczki, D.; Fekete, I.

In: European Journal of Clinical Pharmacology, Vol. 55, No. 5, 1999, p. 349-352.

Research output: Contribution to journalArticle

@article{a089b6170329495ba16c95593f68d52c,
title = "A systematic review of vinpocetine therapy in acute ischaemic stroke",
abstract = "Objectives: To determine whether vinpocetine decreases short- and long- term case fatality and proportion of dependent survivors if administered within 2 weeks of stroke onset. Methods: All published and unpublished trials were attempted to be identified using the standard search strategy of the Cochrane Collaboration Stroke Review Group, using MEDLINE searches performed with all known manufacturer code names and trade names of vinpocetine and by contacting manufacturers of vinpocetine to give information of all randomised controlled trials on vinpocetine in stroke. Researchers who participated in trials on vinpocetine in Hungary were asked for further information. Only truly randomised, unconfounded clinical trials that compared the effect of vinpocetine to either placebo or another reference treatment for acute stroke where treatment started no later than 14 days after stroke onset were eligible for inclusion. Data synthesis and analysis was performed using the Cochrane Review Manager software (Rev Man version 3.0). Results: Among the identified studies on vinpocetine in stroke, only one fulfilled the selection criteria for inclusion in the review. No death occurred in the study groups and no statistically significant difference was found in dependency between the treatment and the placebo groups. No adverse effects were reported. Conclusions: Based on only one small randomised controlled unconfounded study, presently there is not enough evidence to decide whether the administration of vinpocetine does or does not decrease case fatality and dependency in acute stroke.",
keywords = "Human, Ischaemic stroke, Vinpocetine",
author = "D. Bereczki and I. Fekete",
year = "1999",
doi = "10.1007/s002280050639",
language = "English",
volume = "55",
pages = "349--352",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - A systematic review of vinpocetine therapy in acute ischaemic stroke

AU - Bereczki, D.

AU - Fekete, I.

PY - 1999

Y1 - 1999

N2 - Objectives: To determine whether vinpocetine decreases short- and long- term case fatality and proportion of dependent survivors if administered within 2 weeks of stroke onset. Methods: All published and unpublished trials were attempted to be identified using the standard search strategy of the Cochrane Collaboration Stroke Review Group, using MEDLINE searches performed with all known manufacturer code names and trade names of vinpocetine and by contacting manufacturers of vinpocetine to give information of all randomised controlled trials on vinpocetine in stroke. Researchers who participated in trials on vinpocetine in Hungary were asked for further information. Only truly randomised, unconfounded clinical trials that compared the effect of vinpocetine to either placebo or another reference treatment for acute stroke where treatment started no later than 14 days after stroke onset were eligible for inclusion. Data synthesis and analysis was performed using the Cochrane Review Manager software (Rev Man version 3.0). Results: Among the identified studies on vinpocetine in stroke, only one fulfilled the selection criteria for inclusion in the review. No death occurred in the study groups and no statistically significant difference was found in dependency between the treatment and the placebo groups. No adverse effects were reported. Conclusions: Based on only one small randomised controlled unconfounded study, presently there is not enough evidence to decide whether the administration of vinpocetine does or does not decrease case fatality and dependency in acute stroke.

AB - Objectives: To determine whether vinpocetine decreases short- and long- term case fatality and proportion of dependent survivors if administered within 2 weeks of stroke onset. Methods: All published and unpublished trials were attempted to be identified using the standard search strategy of the Cochrane Collaboration Stroke Review Group, using MEDLINE searches performed with all known manufacturer code names and trade names of vinpocetine and by contacting manufacturers of vinpocetine to give information of all randomised controlled trials on vinpocetine in stroke. Researchers who participated in trials on vinpocetine in Hungary were asked for further information. Only truly randomised, unconfounded clinical trials that compared the effect of vinpocetine to either placebo or another reference treatment for acute stroke where treatment started no later than 14 days after stroke onset were eligible for inclusion. Data synthesis and analysis was performed using the Cochrane Review Manager software (Rev Man version 3.0). Results: Among the identified studies on vinpocetine in stroke, only one fulfilled the selection criteria for inclusion in the review. No death occurred in the study groups and no statistically significant difference was found in dependency between the treatment and the placebo groups. No adverse effects were reported. Conclusions: Based on only one small randomised controlled unconfounded study, presently there is not enough evidence to decide whether the administration of vinpocetine does or does not decrease case fatality and dependency in acute stroke.

KW - Human

KW - Ischaemic stroke

KW - Vinpocetine

UR - http://www.scopus.com/inward/record.url?scp=0032838761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032838761&partnerID=8YFLogxK

U2 - 10.1007/s002280050639

DO - 10.1007/s002280050639

M3 - Article

C2 - 10456483

AN - SCOPUS:0032838761

VL - 55

SP - 349

EP - 352

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 5

ER -